A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Summary

This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.

Conditions

• Neoplasm

Interventions

DRUG

PF-00337210

0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous

DRUG

PF-00337210

1mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

2mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

4mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

9mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

8mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

4mg Capsule Twice Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Twice Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Twice Daily (Dose Expansion) Continuous

Sponsors & Collaborators

• University of Wisconsin, Madison

  collaborator OTHER

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-05-31

Primary Completion

2010-10-31

Completion

2011-09-30

Countries

• United States

Study Locations